|
EQS-News: Cantourage Group SE
/ Key word(s): Market Launch
Not for publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction in which such publication or distribution would be unlawful. The important notices at the end of this press release should be observed. Cantourage Group SE launches a range of high-THC medicinal cannabis flowers in Switzerland together with Astrasana Berlin, October 24, 2023 – Cantourage Group SE (hereinafter “Cantourage,” ISIN: DE000A3DSV01, www.cantourage.com), a leading European company for the production and distribution of medical cannabis, has signed a long-term supply agreement for medical cannabis with the Swiss cannabis company Astrasana. On the basis of this agreement, Cantourage will make a selected range of a total of four high-quality medical flowers with a high THC content available starting today. To start with, patients in Switzerland will be able to obtain medical cannabis flowers from the growers LOT 420, Green Karat and Breathing Green from Canada. “We are excited about this partnership with Cantourage that will allow us to bring high-quality medical cannabis flowers with a high THC content to the Swiss market. This represents a significant step for Astrasana and a milestone in the supply of medical cannabis in Switzerland. The collaboration will allow us to meet the increasing demand for high-quality medical products and thus meet the needs of patients,” said Yves Antoniazzi, CEO of Astrasana. “As an emerging company in the medicinal cannabis market, we are very pleased to be able to expand our footprint in Europe together with Astrasana. The range for Astrasana, which features high THC content buds, is already in high demand on the German market. As part of the partnership that has been agreed, we can now jointly set new standards in the supply of medicinal cannabis in Switzerland,” commented Sebastian Blöte, Director of Sales for Europe at Cantourage. The partnership with Cantourage marks a significant development for the supply of medical cannabis in Switzerland. Since the legalization of medical cannabis in August 2022, a wide range of opportunities is opening up, which can now be exploited by Astrasana in collaboration with Cantourage. For the time being, the introduction of the high-quality THC flowers, which are cultivated according to craft standards, will take place exclusively through the Rosengarten Apotheke in Zurich Bassersdorf. The latter specializes in processing and dispensing medical cannabis. Cantourage focuses on producing, releasing and distributing high-quality flowers from cultivation partners around the world according to GMP specifications. This quality and expertise will now be made available to patients in Switzerland through the cooperation with Astrasana. About Astrasana For more information: astrasana.com/en/ About Cantourage For more information: www.cantourage.com/en This announcement does not constitute a public offer or an advertisement for a public offer for sale of securities, in particular within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).
Press contacts for Cantourage:
24.10.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | Cantourage Group SE |
| Feurigstraße 54 | |
| 10827 Berlin | |
| Germany | |
| E-mail: | info@cantourage.com |
| Internet: | https://www.cantourage.com/ |
| ISIN: | DE000A3DSV01 |
| WKN: | A3DSV0 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1755159 |
| End of News | EQS News Service |
|
|
1755159 24.10.2023 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
